[Hong Kong, 10 November 2026] The PolyU Research Centre for Chinese Medicine Innovation (RCMI), the Modernized Chinese Medicine International Association (MCMIA) and the Good Practice in Traditional Chinese Medicine Research Association (GP-TCM RA) successfully co-hosted the University-Industry Collaboration Forum: Navigating Global Regulations to Accelerate Herbal Drug Innovation at The Hong Kong Polytechnic University (PolyU). The Forum brought together leading academics, industry experts, and regulatory officials to explore strategies for overcoming regulatory barriers and advancing innovation in the global herbal medicine sector. Nearly 100 participants attended in person or online, underscoring the significance and timeliness of the theme.
Distinguished speakers including Prof. Dennis CHANG, Director and Professor of Pharmacology of the NICM Health Research Institute, Western Sydney University, Australia; Prof. Rudolf BAUER, Professor Emeritus of the University of Graz, Austria; Dr. MA Yuan-Chun, CEO and Chairman of the Dr. Ma’s Laboratories Inc., Canada; and Prof. LIU Jianping, Director of the Center for Evidence-Based Medicine, Hospital of Chengdu University of Traditional Chinese Medicine, China. They shared the latest developments in herbal pharmacology, standardisation, and regulatory compliance, shedding light on ways to align scientific research with international safety and efficacy standards.
A highlight of the event was the panel discussion featuring prominent leaders from both the clinical and commercial sectors:
- Prof. Bernard M. Y. CHEUNG, Chief Executive Officer of the Greater Bay Area International Clinical Trial Institute, HKSAR, China;
- Prof. Paul LI, Professor, Department of Chemistry of the Simon Fraser University, Canada; and
- Mr. Abraham CHAN, Founder, Chairman and CEO of the PuraPharm Corporation Limited, HKSAR, China.
The panellists engaged in a dynamic discussion on the pathways for translating laboratory research into market-ready products, highlighting the importance of the Greater Bay Area as a hub for clinical trials and the role of international partnerships in meeting global regulatory requirements.
Speaking at the Forum, Dr Vincent CHUNG Chi-ho, Commissioner for Chinese Medicine Development of the HKSAR Government, emphasised the need for cross-sector collaboration to accelerate the translation of research into real-world healthcare solutions. He said: “This Forum underscores our commitment to bridging the gap between academic research and industrial application. By navigating global regulations together, we can ensure that high-quality herbal innovations reach patients safely and efficiently.”
The Forum marked an important step towards strengthening collaboration across the herbal medicine ecosystem. Looking ahead, RCMI will continue to foster dialogue, partnerships and knowledge exchange to advance integrative medicine and natural product research.
【香港,2026年11月9日】香港理工大學(理大)中醫藥創新研究中心、現代中醫藥國際協會及中醫藥規範研究學會於理大合辦「產學研合作論壇:對接國際法規標準,加速草本藥物創新」。論壇匯聚學術界、業界及監管機構代表,共同探討應對法規挑戰的策略,推動全球草本藥物領域的創新發展。近 100 名參加者透過現場或線上方式參與,反映議題備受關注,切合業界當前需要。 論壇邀得多位國際知名專家擔任講者,包括澳洲西悉尼大學藥理學教授兼國家輔助醫學研究院院長張旭東教授、奧地利格拉茨大學榮休教授鲍儒德教授、加拿大馬氏實驗室行政總裁兼主席馬元春博士,以及成都中醫藥大學附屬醫院循證醫學中心主任劉建平教授。各講者分享草本藥理學、標準化及法規合規方面的最新進展,探討如何使科研成果符合國際安全及療效標準。 論壇的一大亮點為專題討論環節,邀得臨床及商界領袖参與: 嘉賓深入探討將實驗室研究成果轉化為市場產品的路徑,並強調粵港澳大灣區作為臨床試驗樞紐的重要地位,以及國際合作在符合全球監管要求方面的關鍵作用。 香港特別行政區政府中醫藥發展專員鍾志豪博士於論壇上致辭時,強調跨界別合作對加快科研成果轉化為實際醫療方案的重要性。他表示:「此次論壇彰顯了我們致力促進學術研究與產業應用對接的決心。透過共同應對全球法規要求,我們能夠確保優質的草本藥物創新成果以安全及高效的方式惠及患者。」 是次論壇為加強草本藥物領域的協作邁出重要一步。展望未來,理大中醫藥創新研究中心將繼續促進跨界別交流、夥伴合作及知識共享,推動整合醫學與天然產物研究的發展。
About the Co-organisers
Research Centre for Chinese Medicine Innovation (RCMI)
The Research Centre for Chinese Medicine Innovation (RCMI) is a constituent research unit established under the PolyU Academy for Interdisciplinary Research (PAIR) with a mission to drive high-impact interdisciplinary Chinese medicine (CM) research. Led by its Director, Prof. WONG Man-sau, Professor in the Department of Food Science and Nutrition of PolyU, the Centre pursues interdisciplinary and translational research to develop novel drugs, new treatment protocols and programmes based on CM practices for applications in the clinical setting or community, thereby translating CM innovations into clinical practice and informing relevant policies.
Modernized Chinese Medicine International Association (MCMIA)
The Modernized Chinese Medicine International Association (MCMIA) is a local non-profit trade organisation established by CM business professionals, scientists and academics. Currently chaired by Mr. Lawrence LO, the Association aims to foster Hong Kong’s development as an international centre for CM by promoting its modernisation and wider adoption of CM, while enhancing professionalism within the industry.
Good Practice in Traditional Chinese Medicine Research Association (GP-TCM RA)
The Good Practice in Traditional Chinese Medicine Research Association (GP-TCM RA) is an international not-for-profit organisation established in 2012, building on the EU-funded FP7 GP-TCM Project. Currently led by its President, Dr. Mei WANG, the Association is dedicated to advancing high-quality, evidence-based research and education in traditional CM and other traditional, complementary and integrative medicines. By promoting good practice guidelines and international standards, fostering interdisciplinary and international collaboration, and organising scientific meetings and training activities, GP-TCM RA seeks to advance traditional CM research and strengthen cooperation among academia, industry, and regulatory bodies worldwide.
關於合辦機構 理大中醫藥創新研究中心 理大中醫藥創新研究中心為理大高等研究院轄下研究單位,致力推動具影響力的交叉學科中醫藥研究。中心由理大食品科學及營養學系教授黃文秀教授擔任主任,透過交叉學科和轉化研究,開發以中醫藥實踐為基礎的新藥、治療方案及項目,供臨床或社區應用,從而將中醫藥創新成果轉化為臨床實踐,並為相關政策提供科研依據。 現代化中醫藥國際協會 現代化中醫藥國際協會是由中醫藥業界、科研家及學者成立的本地非牟利業界組織,現由魯展雨先生擔任會長。協會致力推動中醫藥現代化及更廣泛應用,提升業界專業水平,促進香港發展成為國際中醫藥中心。 中醫藥規範研究學會 中醫藥規範研究學會成立於2012年,是在自歐盟第七框架計劃(FP7)資助的GP-TCM項目基礎上建立的國際非牟利組織。學會目前由會長王梅博士領導,致力推動中醫藥以及其他傳統、輔助與整合醫學領域的高質素循證研究與教育。透過推廣良好研究實踐指引及國際標準、促進跨學科與國際合作,以及舉辦學術會議和培訓活動,推動中醫藥研究發展,並加強全球學術界、業界及監管機構之間的合作。